1.0Market Newsdeskhttps://www.marketnewsdesk.comNewsdeskhttps://www.marketnewsdesk.com/index.php/author/newsdesk/rich600338<blockquote class="wp-embedded-content" data-secret="EIfUw0pR3S"><a href="https://www.marketnewsdesk.com/index.php/mesoblast-board-changes/">Mesoblast Board Changes</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.marketnewsdesk.com/index.php/mesoblast-board-changes/embed/#?secret=EIfUw0pR3S" width="600" height="338" title="“Mesoblast Board Changes” — Market Newsdesk" data-secret="EIfUw0pR3S" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.marketnewsdesk.com/wp-includes/js/wp-embed.min.js </script> NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth. After 12 years of serving on the Board since 2014, Mr William Burns will retire from the Board at the Company’s 2026 Annual General Meeting. Ms Jane Bell AM will take over as Chair of the Nomination and Remuneration Committee, having been co-Chair with Mr Burns since April 2026. The Board recognizes the contribution by Mr Burns to … Continue reading ""https://www.globenewswire.com/newsroom/ti?nf=OTg2NzcxNCM3OTM4ODQyIzIwMTc0MzI=